Macrolide maintenance therapy in patients with bronchiectasis significantly reduces the risk for major adverse cardiovascular events.

Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis. The phase 3 trial ...

Bronchiectasis is a chronic respiratory condition characterized by the abnormal and permanent dilation of the bronchi, leading to persistent cough, sputum production, and recurrent respiratory ...

Insmed (NASDAQ:INSM) shares received continued support from Truist Securities, with analyst Nicole Germino maintaining a Buy ...

New research underscores how air pollution and temperature extremes amplify risks for bronchiectasis patients, pointing to critical measures for safeguarding vulnerable groups. Study: Association ...

Considering taking supplements to treat bronchiectasis? Below is a list of common natural remedies used to treat or reduce the symptoms of bronchiectasis. Follow the links to read common uses ...

Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Insmed (INSM – Research Report). The associated price target remains the ...

In a report released on January 24, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Insmed (INSM – Research Report), with a ...